Literature DB >> 21342371

Viewpoint: Scientific dogmas, paradoxes and mysteries of latent Mycobacterium tuberculosis infection.

Alimuddin Zumla1, Rifat Atun, Markus Maeurer, Peter Mwaba, Zhenkun Ma, Justin O'Grady, Matthew Bates, Keertan Dheda, Michael Hoelscher, John Grange.   

Abstract

Worldwide, there are nearly 10 million new cases of active TB and 1.8 million associated deaths every year. WHO estimates that one-third of the world's population is infected with Mycobacterium tuberculosis (Mtb), forming a huge latent Mtb global reservoir. This renders the prospect of ever eliminating Mtb from the human race almost impossible. Several controversial issues regarding host-pathogen interactions and existing prevention and eradication strategies for latent Mtb infections need to be critically re-examined. In this viewpoint, widely held assumptions on Mtb latency and isoniazid monotherapy and chemoprophylaxis are challenged. We highlight the need for future research to resolve these issues and to develop evidence-based strategies for better understanding of equilibrium and escape of Mtb in the human body, eventually leading to global recommendations for elimination of the latent Mtb state through informed policy and practice. Until such strategies and policies are realized, WHO and TB experts will have to settle for global TB control rather than eradication.
© 2010 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21342371     DOI: 10.1111/j.1365-3156.2010.02665.x

Source DB:  PubMed          Journal:  Trop Med Int Health        ISSN: 1360-2276            Impact factor:   2.622


  17 in total

1.  Eliminating tuberculosis and tuberculosis-HIV co-disease in the 21st century: key perspectives, controversies, unresolved issues, and needs.

Authors:  Alimuddin Zumla; Rifat Atun; Markus Maeurer; Peter S Kim; Patrick Jean-Philippe; Richard Hafner; Marco Schito
Journal:  J Infect Dis       Date:  2012-03-22       Impact factor: 5.226

2.  Isoniazid Preventive Therapy in Contacts of Multidrug-Resistant Tuberculosis.

Authors:  Chuan-Chin Huang; Mercedes C Becerra; Roger Calderon; Carmen Contreras; Jerome Galea; Louis Grandjean; Leonid Lecca; Rosa Yataco; Zibiao Zhang; Megan Murray
Journal:  Am J Respir Crit Care Med       Date:  2020-10-15       Impact factor: 21.405

3.  Cerebral tuberculoma mimicking brain tumor.

Authors:  S Greschus; K Kuchelmeister; S Oeynhausen; H P Fischer; H Urbach
Journal:  Clin Neuroradiol       Date:  2013-09-04       Impact factor: 3.649

4.  Protection against Mycobacterium leprae infection by the ID83/GLA-SE and ID93/GLA-SE vaccines developed for tuberculosis.

Authors:  Malcolm S Duthie; Rhea N Coler; John D Laurance; Lucas H Sampaio; Regiane M Oliveira; Ana Lucia M Sousa; Mariane M A Stefani; Yumi Maeda; Masanori Matsuoka; Masahiko Makino; Steven G Reed
Journal:  Infect Immun       Date:  2014-07-14       Impact factor: 3.441

5.  Host directed therapies (HDTs) and immune response signatures: insights into a role for interleukin-32.

Authors:  Markus Maeurer; Martin Rao; Alimuddin Zumla
Journal:  Ann Transl Med       Date:  2015-05

6.  Contribution of efflux to the emergence of isoniazid and multidrug resistance in Mycobacterium tuberculosis.

Authors:  Diana Machado; Isabel Couto; João Perdigão; Liliana Rodrigues; Isabel Portugal; Pedro Baptista; Bruno Veigas; Leonard Amaral; Miguel Viveiros
Journal:  PLoS One       Date:  2012-04-06       Impact factor: 3.240

7.  Implementing the global plan to stop TB, 2011-2015--optimizing allocations and the Global Fund's contribution: a scenario projections study.

Authors:  Eline L Korenromp; Philippe Glaziou; Christopher Fitzpatrick; Katherine Floyd; Mehran Hosseini; Mario Raviglione; Rifat Atun; Brian Williams
Journal:  PLoS One       Date:  2012-06-18       Impact factor: 3.240

8.  miRNA signatures in sera of patients with active pulmonary tuberculosis.

Authors:  Paolo Miotto; Grace Mwangoka; Ilaria C Valente; Luca Norbis; Giovanni Sotgiu; Roberta Bosu; Alessandro Ambrosi; Luigi R Codecasa; Delia Goletti; Alberto Matteelli; Elias N Ntinginya; Francesco Aloi; Norbert Heinrich; Klaus Reither; Daniela M Cirillo
Journal:  PLoS One       Date:  2013-11-21       Impact factor: 3.240

9.  A broad profile of co-dominant epitopes shapes the peripheral Mycobacterium tuberculosis specific CD8+ T-cell immune response in South African patients with active tuberculosis.

Authors:  Rebecca Axelsson-Robertson; André G Loxton; Gerhard Walzl; Marthie M Ehlers; Marleen M Kock; Alimuddin Zumla; Markus Maeurer
Journal:  PLoS One       Date:  2013-03-26       Impact factor: 3.240

Review 10.  Challenges in the research and development of new human vaccines.

Authors:  T Barbosa; M Barral-Netto
Journal:  Braz J Med Biol Res       Date:  2013-02       Impact factor: 2.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.